Providing Consultative DMPK Solutions Bridging Drug Discovery and Development
21 Nov 2013

XenoTech and XenoGesis work together to facilitate outsourced drug metabolism and pharmacokinetics (DMPK) studies from early stage drug discovery through development and beyond. The partnership was developed to help mitigate the risk and cost associated with clinical failure. Efficacy and safety are now the leading causes of attrition and are linked to drug exposure in target and off-target tissues. While pharmacokinetics is no longer the leading cause of failure, a drug’s exposure is driven by its pharmacokinetic properties and ultimately remains critical for successful pharmacodynamics and safety. This webinar will showcase the consultative basis of the DMPK CRO alliance and highlight the capabilities with real-life examples of our unique combination of expertise.

Xenotech LLC